FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2908867939> ?p ?o ?g. }

• W2908867939 abstract "Background Atacicept is an antagonist of the B cell regulatory factors BLyS (B lymphocyte stimulator) and APRIL (a proliferation inducing ligand). It is capable of binding to all known conformations of BLyS and APRIL and is thus expected to modulate the maturation, differentiation, and effector function of B cells. We aimed to define the relationship between atacicept drug exposure and pharmacodynamic (PD) effects in vivo. Here, we report results of our study examining the effects of atacicept on the immune response in a keyhole limpet hemocyanin (KLH) challenge model in cynomolgus monkeys. Methods Cynomolgus monkeys (Macaca fascicularis) were injected with KLH on Day −33, and on Day 1 received the first dose of either atacicept (0.3, 3, or 30 mg/kg) or vehicle followed by a KLH challenge. Animals were dosed weekly (Day 1, 8, 15) and were subsequently monitored for 2 weeks before the study ended on Day 29. Clinical signs, total and free drug levels, peripheral blood B and T cell subpopulations, and total and KLH-specific immunoglobulin (Ig) levels were monitored. Additionally, gene expression in blood was analysed using the NanoString nCounter platform. Results Atacicept was well-tolerated at all dose levels tested. All animals in the treatment arms had quantifiable levels of atacicept in serum throughout the study. Reduction of serum IgM and IgG was detected 7 days after treatment, with a continuous reduction in the mean serum IgM and IgG levels observed until Day 29 (table 1). In animals treated with 3 and 30 mg/kg atacicept, a significant decrease in serum anti-KLH IgG levels was observed versus vehicle-treated controls, beginning at Day 11 (table 2). A minor reduction in absolute CD3-CD20+, IgD +B cell numbers was seen in response to treatment, but no changes in T cell subsets were detected. Changes in gene expression following atacicept treatment were predominantly observed in B cell-related and Ig genes. Conclusions This study showed that atacicept modulates B cell responses, IgM and IgG levels, and Ig isotype switching in a KLH-antigen-challenged cynomolgus monkey model, thus supporting its use in the treatment of antibody-mediated diseases. Additionally, gene expression PD markers identified in this study will be used in subsequent clinical trials as exploratory PD readouts. Disclosure of Interest E. Samy Employee of: EMD Serono Research and Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), A. Bender Employee of: EMD Serono Research and Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Y. Wu Employee of: EMD Serono Research and Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), V. Castagna Employee of: Istituto di Ricerche Biomediche Antoine Marxer RBM SpA, an affiliate of Merck KGaA, E. Bertotti Employee of: Istituto di Ricerche Biomediche Antoine Marxer RBM SpA, an affiliate of Merck KGaA, R. Boggio Employee of: Istituto di Ricerche Biomediche Antoine Marxer RBM SpA, an affiliate of Merck KGaA, A. Paoletti Employee of: Istituto di Ricerche Biomediche Antoine Marxer RBM SpA, an affiliate of Merck KGaA, S. Riva Employee of: Istituto di Ricerche Biomediche Antoine Marxer RBM SpA, an affiliate of Merck KGaA, P. Schneider Grant/research support from: EMD Serono Research and Development Institute, Inc. and Merck KGaA, P. Haselmayer Employee of: Merck KGaA, J. DeMartino Employee of: EMD Serono Research and Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany)" @default.
• W2908867939 created "2019-01-25" @default.
• W2908867939 creator A5002425824 @default.
• W2908867939 creator A5007113941 @default.
• W2908867939 creator A5011547050 @default.
• W2908867939 creator A5016182569 @default.
• W2908867939 creator A5025754018 @default.
• W2908867939 creator A5030509828 @default.
• W2908867939 creator A5039188772 @default.
• W2908867939 creator A5055486511 @default.
• W2908867939 creator A5057108334 @default.
• W2908867939 creator A5072303880 @default.
• W2908867939 creator A5085444021 @default.
• W2908867939 date "2018-06-01" @default.
• W2908867939 modified "2023-09-26" @default.
• W2908867939 title "FRI0272 Pharmacodynamic effects of atacicept treatment in a cynomolgus monkey klh antigen challenge model" @default.
• W2908867939 doi "https://doi.org/10.1136/annrheumdis-2018-eular.3712" @default.
• W2908867939 hasPublicationYear "2018" @default.
• W2908867939 type Work @default.
• W2908867939 sameAs 2908867939 @default.
• W2908867939 citedByCount "0" @default.
• W2908867939 crossrefType "proceedings-article" @default.
• W2908867939 hasAuthorship W2908867939A5002425824 @default.
• W2908867939 hasAuthorship W2908867939A5007113941 @default.
• W2908867939 hasAuthorship W2908867939A5011547050 @default.
• W2908867939 hasAuthorship W2908867939A5016182569 @default.
• W2908867939 hasAuthorship W2908867939A5025754018 @default.
• W2908867939 hasAuthorship W2908867939A5030509828 @default.
• W2908867939 hasAuthorship W2908867939A5039188772 @default.
• W2908867939 hasAuthorship W2908867939A5055486511 @default.
• W2908867939 hasAuthorship W2908867939A5057108334 @default.
• W2908867939 hasAuthorship W2908867939A5072303880 @default.
• W2908867939 hasAuthorship W2908867939A5085444021 @default.
• W2908867939 hasBestOaLocation W29088679391 @default.
• W2908867939 hasConcept C111113717 @default.
• W2908867939 hasConcept C112705442 @default.
• W2908867939 hasConcept C126322002 @default.
• W2908867939 hasConcept C159654299 @default.
• W2908867939 hasConcept C170286685 @default.
• W2908867939 hasConcept C203014093 @default.
• W2908867939 hasConcept C2776727803 @default.
• W2908867939 hasConcept C2778453870 @default.
• W2908867939 hasConcept C71924100 @default.
• W2908867939 hasConcept C98274493 @default.
• W2908867939 hasConceptScore W2908867939C111113717 @default.
• W2908867939 hasConceptScore W2908867939C112705442 @default.
• W2908867939 hasConceptScore W2908867939C126322002 @default.
• W2908867939 hasConceptScore W2908867939C159654299 @default.
• W2908867939 hasConceptScore W2908867939C170286685 @default.
• W2908867939 hasConceptScore W2908867939C203014093 @default.
• W2908867939 hasConceptScore W2908867939C2776727803 @default.
• W2908867939 hasConceptScore W2908867939C2778453870 @default.
• W2908867939 hasConceptScore W2908867939C71924100 @default.
• W2908867939 hasConceptScore W2908867939C98274493 @default.
• W2908867939 hasLocation W29088679391 @default.
• W2908867939 hasOpenAccess W2908867939 @default.
• W2908867939 hasPrimaryLocation W29088679391 @default.
• W2908867939 hasRelatedWork W2321247502 @default.
• W2908867939 hasRelatedWork W2414621353 @default.
• W2908867939 hasRelatedWork W2415093757 @default.
• W2908867939 hasRelatedWork W2415504189 @default.
• W2908867939 hasRelatedWork W2806121327 @default.
• W2908867939 hasRelatedWork W2947290897 @default.
• W2908867939 isParatext "false" @default.
• W2908867939 isRetracted "false" @default.
• W2908867939 magId "2908867939" @default.
• W2908867939 workType "article" @default.